These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

113 related items for PubMed ID: 7116223

  • 1. Effect of salicylate on the fate of [14C]sulfinpyrazone in the rat.
    Wong LT, Buttar HS, Solomonraj G, Thomas BH.
    Can J Physiol Pharmacol; 1982 Jun; 60(6):763-8. PubMed ID: 7116223
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Study on the metabolic fate of catena-(S)-[mu-[N alpha-(3- aminopropionyl)histidinato(2-)-N1,N2,O:N tau]-zinc]. 1st communication: absorption, distribution, metabolism and excretion after single administration to rats.
    Sano H, Furuta S, Toyama S, Miwa M, Ikeda Y, Suzuki M, Sato H, Matsuda K.
    Arzneimittelforschung; 1991 Sep; 41(9):965-75. PubMed ID: 1796927
    [Abstract] [Full Text] [Related]

  • 6. Effect of sodium salicylate on the fate of warfarin in the rat.
    Coldwell BB, Buttar HS, Paul CJ, Thomas BH.
    Toxicol Appl Pharmacol; 1974 Jun; 28(3):374-84. PubMed ID: 4851695
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics of 4-acetylaminophenylacetic acid. 1st communication: absorption, distribution, metabolism and excretion in mice, rats, dogs and monkeys after single administration of 14C-labeled compound.
    Sugihara K, Morino A, Nomura A, Iida S, Sugiyama M.
    Arzneimittelforschung; 1990 Jul; 40(7):800-5. PubMed ID: 2222556
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Disposition and metabolism of the new hypocholesterolemic compound S-8921 in rats and dogs.
    Yamaguchi T, Nakajima Y, Mizobuchi M, Inazawa K, Kanazu T, Kadono K, Ohkawa T, Iwatani K.
    Arzneimittelforschung; 1998 Oct; 48(10):995-1006. PubMed ID: 9825117
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Disposition in rats and dogs of ciglitazone, a new antidiabetic agent.
    Torii H, Yoshida K, Tsukamoto T, Tanayama S.
    Xenobiotica; 1984 Mar; 14(3):259-68. PubMed ID: 6711015
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. New metabolites of sulfinpyrazone in man.
    Dieterle W, Faigle JW, Moppert J.
    Arzneimittelforschung; 1980 Mar; 30(6):989-93. PubMed ID: 7191279
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Pharmacokinetics of NS-49, a phenethylamine class alpha 1A-adrenoceptor agonist. 1st communication: absorption and excretion in rats after a single administration of 14C-NS-49.
    Mukai H, Watanabe S, Morino A.
    Arzneimittelforschung; 1999 May; 49(5):434-40. PubMed ID: 10367106
    [Abstract] [Full Text] [Related]

  • 19. Excretion of sulfinpyrazone in the rat.
    Aldridge A, Johnson GE.
    Can J Physiol Pharmacol; 1972 Nov; 50(11):1061-5. PubMed ID: 4640798
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.